Frontera Therapeutics’ Hong Kong IPO Application Lapses, Focused on Recombinant AAV Gene Therapy
NewTimeSpace News: Per information published on the official website of the Hong Kong Stock Exchange, the Main Board listing application filed by Frontera Therapeutics on 23 December 2025 has recently lapsed after the six-month validity period expired. UBS Group and Haitong International served as joint sponsors upon the initial filing.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- NewTimeSpace | "The First AAV Gene Therapy Stock", Frontera Therapeutics Files for Hong Kong IPO
- XINTE ENERGY (01799.HK): Nan Xinjian Resigns as General Manager and Executive Director; Wang Bin Appointed General Manager and Proposed as Executive Director
- PINESTONE (00804.HK): Net Proceeds of HKD 24.2 Million from Placing for Virtual Asset Licence Application and AI Application Expansion
- MICROTECH MED-B (02235.HK): Enters Raw Material Purchase Framework Agreement with Connected Person Hangzhou Shukang
- DETAI NEWENERGY (00559.HK): Enters Memorandum of Understanding for Proposed Acquisition of HKD 505 Million; Trading Remains Suspended
